Annexon (ANNX) Cash from Investing Activities (2019 - 2026)

Annexon's (ANNX) quarterly Cash from Investing Activities came in at $27.1 million in Q1 2026, down 72.28% year-on-year from $97.6 million in Q1 2025, and up 202.02% quarter-over-quarter from -$26.5 million in Q4 2025.

Annexon (ANNX) Cash from Investing Activities (2019 - 2026) Analysis & Trends

Annexon's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $27.1 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 72.28% year-over-year to $27.1 million in Q1 2026; TTM through Mar 2026 was $119.5 million, a 372.34% increase from a year earlier, with the FY2025 full-year figure at $190.1 million, up 186.86% from the prior year.
  • Cash from Investing Activities grew to $27.1 million in Q1 2026 per ANNX's latest filing, from -$26.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $97.6 million in Q1 2025 and bottomed at -$96.6 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is $14.1 million (2022), against an average of $7.5 million.
  • Across the five-year window, Cash from Investing Activities surged 1203.13% in 2022 and plunged 2720.65% in 2025, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$43.6 million in 2022, then soared by 94.99% to -$2.2 million in 2023, then jumped by 146.36% to $1.0 million in 2024, then plunged by 2720.65% to -$26.5 million in 2025, then soared by 202.02% to $27.1 million in 2026.
  • Per Business Quant, the three latest ANNX Cash from Investing Activities figures stand at $27.1 million (Q1 2026), -$26.5 million (Q4 2025), and $45.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn - -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 470.97 Bn 466.18 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 122.29 Bn 115.05 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.43 Bn 34.42 Bn 959.66 Mn -25.54 Mn
10 Annexon 1.03 Bn 1.03 Bn - 27.06 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 27.06 Mn
Mar 31, 2026 27.06 Mn
Dec 31, 2025 -26.52 Mn
Dec 31, 2025 -26.52 Mn
Sep 30, 2025 45.87 Mn
Sep 30, 2025 45.87 Mn
Jun 30, 2025 73.08 Mn
Jun 30, 2025 73.08 Mn
Mar 31, 2025 97.62 Mn
Mar 31, 2025 97.62 Mn
Dec 31, 2024 1.01 Mn
Dec 31, 2024 1.01 Mn
Sep 30, 2024 -45.93 Mn
Sep 30, 2024 -45.93 Mn
Jun 30, 2024 -96.58 Mn
Jun 30, 2024 -96.58 Mn
Mar 31, 2024 -77.30 Mn
Mar 31, 2024 -77.30 Mn
Dec 31, 2023 -2.18 Mn
Dec 31, 2023 -2.18 Mn